As global markets navigate the challenges posed by rising U.S. Treasury yields and a cautious economic outlook, investors are increasingly focused on growth stocks, which have shown resilience in the current environment. In this context, companies with high insider ownership can be particularly appealing as they often signal confidence from those who know the business best.
Name | Insider Ownership | Earnings Growth |
Lavvi Empreendimentos Imobiliários (BOVESPA:LAVV3) | 11.9% | 21.1% |
Archean Chemical Industries (NSEI:ACI) | 22.9% | 34% |
Kirloskar Pneumatic (BSE:505283) | 30.3% | 26% |
Arctech Solar Holding (SHSE:688408) | 37.8% | 29.8% |
Laopu Gold (SEHK:6181) | 36.4% | 33.2% |
Seojin SystemLtd (KOSDAQ:A178320) | 30.7% | 49.1% |
Medley (TSE:4480) | 34% | 30.4% |
Findi (ASX:FND) | 35.8% | 64.8% |
HANA Micron (KOSDAQ:A067310) | 18.3% | 105.8% |
UTI (KOSDAQ:A179900) | 33.1% | 134.6% |
Click here to see the full list of 1510 stocks from our Fast Growing Companies With High Insider Ownership screener.
We're going to check out a few of the best picks from our screener tool.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: F-Secure Oyj is a cybersecurity company based in Finland that operates internationally, with a market cap of €353.71 million.
Operations: The company generates revenue from its Consumer Security segment, which amounted to €146.13 million.
Insider Ownership: 37%
Earnings Growth Forecast: 15.5% p.a.
F-Secure Oyj's recent earnings report highlights a modest increase in sales and net income for the third quarter, with sales reaching €36.35 million and net income at €6.71 million. Despite being dropped from the S&P Global BMI Index, F-Secure shows potential as a growth company with insider ownership interests aligning management with shareholder goals. The company's earnings are forecast to grow faster than the Finnish market at 15.5% annually, although profit margins have declined recently.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. is a biopharmaceutical company focused on the research, development, production, and sale of pharmaceutical products for diagnosing and treating allergic diseases in China and internationally, with a market cap of CN¥12.90 billion.
Operations: The company generates revenue primarily from its activities in research, development, production, and sales of pharmaceuticals amounting to CN¥904.64 million.
Insider Ownership: 11.2%
Earnings Growth Forecast: 25.3% p.a.
Zhejiang Wolwo Bio-Pharmaceutical reported a modest increase in earnings, with net income reaching CNY 272.25 million for the first nine months of 2024. Despite a volatile share price recently, the company is expected to see significant annual profit growth of 25.3%, outpacing the broader Chinese market. Revenue is also forecast to grow at an impressive rate of 22.4% annually, although its dividend history remains unstable and insider trading activity has been minimal lately.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Nan Juen International Co., Ltd. focuses on the research, development, manufacture, and trading of steel ball guide rails in Taiwan with a market cap of NT$12.10 billion.
Operations: The company generates revenue of NT$1.65 billion from the manufacture and sales of steel ball slide rails.
Insider Ownership: 15.7%
Earnings Growth Forecast: 95.6% p.a.
Nan Juen International's earnings surged by a very large amount over the past year, with forecasts indicating continued strong growth of 95.6% annually, outpacing Taiwan's market. Revenue is expected to grow faster than 20% per year, trading at 42.1% below estimated fair value despite recent share price volatility. The company has been added to the S&P Global BMI Index and recently announced a TWD 802.9 million fixed-income offering with zero coupon secured notes due in 2027.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include HLSE:FSECURE SZSE:300357 and TPEX:6584.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.